La terapia con CAR-T dell’Ospedale Bambino Gesù di Roma ha fatto sparire in giovani pazienti alcune malattie autoimmuni molto gravi.
È un orgoglio tutto italiano del quale ringraziamo il Professor Franco Locatelli, il Dottor Fabrizio De Benedetti e tutto il loro team.
#Noos
📅 Thursday, 2 April 2026
🕛 13:00 - 14:00 CET
Don't miss out on the next 𝗣𝗥𝗘𝗦 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝘁𝗼𝗿𝘆 𝗖𝗼𝘂𝗿𝘀𝗲 of 2026, focusing on Immunoprophylaxis.
𝗟𝗮𝘀𝘁 𝗰𝗵𝗮𝗻𝗰𝗲 𝘁𝗼 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿! 🔗 https://t.co/HRUdbeiFe3
Il Bambino Gesù è stato inserito anche quest'anno nella classifica World's Best Hospitals, l'elenco dei migliori ospedali al mondo stilato dal 2019 dalla rivista statunitense Newsweek insieme a Statista
Becilli, Metzler, Bracaglia et al. treated 8 children with severe/refractory autoimmune diseases (AD) with one dose of CD19 CAR T cells to reset the dysregulated immune system. CAR T cells were successfully manufactured for all patients, and promoted clearance of CD19+ cells within the first week. Furthermore, a strong and durable decrease in autoantibody titers was noted. At a median follow-up of 16.5 months, substantial improvements/resolution of AD was observed in all patients, enabling sustained discontinuation of immunosuppressive therapies, even after B cell reconstitution. Grade 1 CRS was reported in 6 patients, and ICANS were reported in 1 patient. https://t.co/NJy8KTV0PD @MarcoBecilli@claudiabrac
"Non avevamo mai visto una remissione clinica così profonda con le terapie tradizionali". Il commento del dottor Fabrizio De Benedetti sui risultati dello studio che dimostra l'efficacia delle cellule CAR-T nelle malattie autoimmuni dell'età pediatrica.
https://t.co/8Ft3JlW4hL
Il commento del prof. Franco Locatelli sullo studio coordinato dall'Ospedale Bambino Gesù che dimostra l'efficacia delle cellule CAR-T nelle #malattieautoimmuni pediatriche. Gli otto pazienti coinvolti hanno potuto interrompere completamente le terapie immunosoppressive.
Su @NatureMedicine lo studio coordinato dall'Ospedale che dimostra L’efficacia delle cellule CAR-T nelle #malattieautoimmuni dell’età pediatrica. Sette bambini su otto in remissione completa, tutti hanno sospeso le terapie immunosoppressive.
https://t.co/8Ft3JlWC7j
Su @NatureMedicine lo studio coordinato dall'Ospedale che dimostra L’efficacia delle cellule CAR-T nelle #malattieautoimmuni dell’età pediatrica. Sette bambini su otto in remissione completa, tutti hanno sospeso le terapie immunosoppressive.
https://t.co/8Ft3JlWC7j
Among 66 patients with Still's disease receiving first-line IL-1 inhibitor therapy, IL-18 levels, particularly at 3 months after IL-1i initiation, could predict long-term disease activity, risk of MAS, and chronic-persistent disease trajectory
A&R
https://t.co/FhyXxorp6F
@sjiafoundation#Stills & #SJIA patient/family event
BUILDING STILL'S DISEASE ADVOCACY IN EUROPE: RESEARCH, CARE PATHWAYS & THE PATIENT VOICE
Jan 10th, 10AM ET = 4pm CET
FREE registration: https://t.co/en6vgnaLZP
@claudiabrac@ChristophKessel F. Minoia, B Vastert
🌟"Pediatric Year in Review" was a great session at #ACR25 led by two CARRA members, Peter Nigrovic, M.D. and Karen Onel, M.D. They expertly summarized #pedsrheum research highlights of 2025 - in both basic science and clinical research. Read more ➡️https://t.co/t01Svi2EzO
Hey #IEI and #autoinflammation enthusiasts, and #ACR2025 attendees
Registration is free https://t.co/SUmD9oQx4A
But pls consider supporting via @AAlliance_SAID https://t.co/HHfEtKp4DS
Investigating peripheral innate lymphoid cells in children with systemic JIA in remission revealed decreased frequency and number of NK cells, suggesting persistent dysregulation of innate immune cells even in the absence of active disease symptoms
A&R
https://t.co/uP88NvCYkF